Form 4: Gyre Therapeutics President Sells Shares Under 10b5-1 Trading Plan

Songjiang Ma, President of Gyre Therapeutics, sold shares of common stock on February 10th and 11th, 2025, under a pre-arranged 10b5-1 trading plan.

Summary

• Songjiang Ma, the President of Gyre Therapeutics, sold shares of the company's common stock on February 10th and 11th, 2025.
• The sales were executed under a Rule 10b5-1 trading plan adopted on September 13, 2024.
• On February 10th, 2,000 shares were sold at a weighted average price of $11.9, with prices ranging from $11.72 to $12.12.
• On February 11th, 1,878 shares were sold at a weighted average price of $11.52, with prices ranging from $11.45 to $11.61.
• Following these transactions, Mr. Ma directly owns no shares, but indirectly owns 2,875,260 shares through his spouse.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing related to stock sales under a pre-arranged trading plan. It doesn't inherently indicate positive or negative sentiment, but the market reaction could vary.

Risks

• Executive stock sales can sometimes be perceived negatively by investors, potentially leading to downward pressure on the stock price.

Industry Context

Sales by company presidents are common and often part of personal financial planning. The use of a 10b5-1 plan suggests the sales were pre-planned and not based on inside information at the time of the transactions.

Stakeholder Impact

• Shareholders may react to the news of the stock sales, although the existence of a 10b5-1 plan may mitigate concerns about insider trading.

Key Dates

Keywords

Form 4, Gyre Therapeutics, Songjiang Ma, stock sale, 10b5-1 trading plan, insider trading